Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

BACKGROUND: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494676/
https://www.ncbi.nlm.nih.gov/pubmed/32927274
http://dx.doi.org/10.1016/j.ebiom.2020.102990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494676/
https://www.ncbi.nlm.nih.gov/pubmed/32927274
http://dx.doi.org/10.1016/j.ebiom.2020.102990

Ejemplares similares